| INFLARX N.V. EO 0,12 |
| Niederlande |
| Gesundheit |
| NL0012661870 / A2H7A5 |
| IF0 (Frankfurt) / IFRX (NASDAQ) |
| FRA:IF0, ETR:IF0, IF0:GR, NASDAQ:IFRX |
| - |
| https://www.inflarx.de/ |
|
InflaRx N.V. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing anti-inflammatory therapies that target the complement system, particularly the C5a and C5aR pathways. The company’s portfolio center..
>Volltext.. |
| 231.47 Mio. EUR |
| 74.34 Mio. EUR |
| - |
| - |
| - |
| - |
| 0.85 Mio. EUR |
| 149.13 Mio. EUR |
| - |
| 7.88 |
| - |
| - |
| - |
| - |
| - |
| - |
| INFLARX |
| 04.11.26 |
|